期刊
METABOLITES
卷 12, 期 3, 页码 -出版社
MDPI
DOI: 10.3390/metabo12030238
关键词
non-alcoholic fatty liver disease; non-alcoholic steatohepatitis; nuclear receptors; lipogenesis; metabolism; inflammation; glucose metabolism; oxidative stress; insulin sensitivity; fibrosis; therapeutics
Non-alcoholic fatty liver (NAFLD) is a metabolic pandemic linked to a collection of metabolic diseases. Nuclear receptors are key regulators of metabolism, and targeting them for NAFLD treatment is promising. Several compounds, including Cilofexor, thiazolidinediones, and Saroglitazar, are currently undergoing clinical trials.
Non-alcoholic fatty liver (NAFLD) over the past years has become a metabolic pandemic linked to a collection of metabolic diseases. The nuclear receptors ERRs, REV-ERBs, RORs, FXR, PPARs, and LXR are master regulators of metabolism and liver physiology. The characterization of these nuclear receptors and their biology has promoted the development of synthetic ligands. The possibility of targeting these receptors to treat NAFLD is promising, as several compounds including Cilofexor, thiazolidinediones, and Saroglitazar are currently undergoing clinical trials. This review focuses on the latest development of the pharmacology of these metabolic nuclear receptors and how they may be utilized to treat NAFLD and subsequent comorbidities.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据